Huadong Pharmaceutical announced on the evening of June 10 that Huadong, a wholly-owned subsidiary, received a “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. An application for a multi-center, randomized, double-blind, parallel-controlled excipient phase III clinical trial evaluating the efficacy and safety of 0.3% rofloxate foam in patients with seborrheic dermatitis was approved by Huadong from China and the US.

Huadong Pharmaceutical announced on the evening of June 10 that Huadong, a wholly-owned subsidiary, received a “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. An application for a multi-center, randomized, double-blind, parallel-controlled excipient phase III clinical trial evaluating the efficacy and safety of 0.3% rofloxate foam in patients with seborrheic dermatitis was approved by Huadong from China and the US.